AxoGen, Inc. (AXGN)

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

2 Medical-Device Stocks Lighting Up the Options Pits

Axogen, Inc. (AXGN) M&A Call Transcript

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

AxoGen Q2 Earnings Call Highlights

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

Axogen, Inc. Reports Second Quarter 2026 Financial Results